



Jupiter Neurosciences Corporate Introduction: Noble Conference

(NASDAQ: JUNS)

December 2025



CAUTIONARY NOTE ON FORWARD LOOKING STATEMENTS

This Presentation contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. Factors that could cause such differences, but are not limited to, are our strategy, future operations, regulatory process, future financial position, future revenue, projected costs, prospects, plans, objectives of management, expected market growth, our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this Presentation and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to update or revise any forward-looking statement, whether as a result of uncertainties and assumptions.

MARKET, INDUSTRY AND OTHER DATA

This presentation includes market and industry data and forecasts that the Company has developed from independent research reports, publicly available information, various industry publications, other published industry sources or the Company’s internal data and estimates. Independent research reports, industry publications and other published industry sources generally indicate that the information contained therein was obtained from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. Although the Company believes that the publications and reports are reliable, the Company has not independently verified the data and makes no representation or warranty with respect to the accuracy of such information. Any and all trademarks and trade names referred to in this presentation are the property of their respective owners. The Company’s internal data, estimates and forecasts are based on information obtained from trade and business organizations and other contracts in the markets in which it operates and management’s understanding of industry conditions. Although the Company believes that such information is reliable, the Company has not had such information verified by any independent sources.



Investment Highlights

Significant research and corporate accomplishments; positioned to execute several steps in 2025 and 2026

- ✓ **Breakthrough Therapeutics Platform — JOTROL™:** Proprietary micellar resveratrol delivery system achieves ~9× higher bioavailability, penetrates the CNS, is **patent-protected through 2036**, and is entering a Phase IIa Parkinson's trial
- ✓ **Dual-Engine Strategy: Therapeutics + Consumer Longevity:** Launching **Nugevia™**, a direct-to-consumer longevity supplement line (GLO, PWR, MND) in Q3 2025, generating near-term high-margin revenues while supporting the clinical pipeline. Tapping into **\$8T longevity** market.
- ✓ **Expanding Clinical Pipeline:** Beyond Parkinson's, JOTROL™ is being explored in Alzheimer's, MPS-I, Friedreich's Ataxia, MELAS, and metabolic/obesity indications—addressing a combined CNS and neuroinflammation market exceeding **\$50 billion**
- ✓ **Science and Ambassador-Driven Consumer Momentum**
Nugevia™'s brand power is based on the pharmaceutical developed science supported by its scientific advisory board and enhanced by ambassadors like Annika Sörenstam and Chris Webber, reinforcing credibility in the \$8 trillion global longevity and wellness market

Latest Developments: a) IND approved by the FDA for a Phase IIa clinical trial in Parkinson's patients b) \$20 M non-toxic SEPA financing securing ample cash to execute Phase II trial and aggressive marketing launch of the Nugevia product line. c) Nugevia DTC-sales initiated..

JOTROL™ - Broad Applicability Across Disease Areas

JOTROL™'s micellar system allows therapeutic dosing without gastrointestinal toxicity, a major barrier for competitors, giving Jupiter a **defensible IP position** and potential for regulatory approvals across indications.

Alzheimer's Disease


Targeting neuroinflammation and cognitive decline

Longevity & Healthspan

Extending healthy aging through cellular protection

Mental Health

Neuroinflammation's role in psychiatric conditions



Parkinson's Disease

Addressing motor symptoms and neurodegeneration

Rare Diseases

Orphan drug opportunities in genetic disorders

Mitochondrial Disorders

Restoring cellular energy production

Comprehensive R&D Pipeline



One completed Phase I (healthy volunteers) is the safety/tolerability gate that **lets multiple programs start at Phase II**



Lead program – Parkinson’s disease: Present focus; advancing into Phase II based on supportive preclinical results



Why PD first - In the established **MPTP PD model**, JOTROL™ showed beneficial neurologic effects (rotarod speed/time, grip strength)



Next in line – Alzheimer’s/MCI: Planned **after PD data**; AD study planning is **actively guided** by advisors (e.g., MIT/Harvard-MGH)



Optional expansion – Rare diseases: MPSI and MELAS can be activated based on PD/AD signals



Phase IIA JOTROL™ PD Study

➤ Milestones

- IND granted Oct 2025
- GMP material production complete
- Trial activation ongoing
- FPI expected late Q1/early Q2 2026

➤ Trial Design

- 30 PD patients
- Randomized into placebo/MAD design
- Oral administration of study drug
- Once daily administration over the course of 12 weeks

➤ Study Objectives

- Primary Objectives – Safety and Pharmacokinetics
- Secondary Objectives – Biomarker and Target Engagement
- Exploratory Objectives – Clinical outcomes via MDS-UPDRS, MoCA, TUG, CGI, PDQ-39, NLRP3

Nugevia™ - DTC Consumer Supplements

Nugevia isn't just Jupiter's consumer brand, it's a dual-purpose platform that delivers high-margin revenue today while generating real-world data that strengthens clinical trials.

- Launched in Q3 2025, Nugevia positions Jupiter in the **\$8 trillion global longevity** market, with premium formulations designed for compliance and high margins.
- Direct-to-consumer distribution **maximizes gross margins and builds a direct relationship with customers**, creating a foundation for **repeat purchases** and brand loyalty.
- Every Nugevia purchase provides structured opportunities to **collect outcomes data** (focus, energy, stress recovery, skin health) through surveys, apps, and wearables.



Consumer brand is backed by growing roster of high-profile brand ambassadors and scientists enhancing credibility and reach.

- Annika Sörenstam, the most accomplished female professional golfer in history, joined Nugevia as its first brand ambassador.
- Chris Webber, NBA Hall of Famer and five-time All-Star, was later announced as another ambassador.
- Charbel Moussa, Professor of Neurology, Georgetown University



Management

Strong management team and advisors with extensive international experience and a track record for successfully building organizations that can take a product from inception to commercialization.

Christer "Chris" Rosén



Chairman, CEO & Founder. Serial entrepreneur, inventor and team builder with over 20 years in executive Biotech positions.

Alexander Rosén



Our CAO and Co-Founder. Went from professional golf to finance and administration, spending the last 6 years as Controller and head of admin in the Biotech industry.

Marshall Hayward, Ph.D




Our CSO and Co-Founder is an experienced pharma product developer, with VP and C-suite roles in large and small pharmaceutical companies, with several product approvals achieved in large and small companies.

Alison D. Silva



Our CBO/President and Director brings today's view on the rare disease business and financing. Former CEO for a publicly traded rare disease company. Founder of the Orphan Group, a consulting firm regarding all aspects of rare diseases.

Saleem Emasri, CPA



Our CFO is the owner of Titan Advisory Services, LLC. Saleem has years of background in taking companies public. He also spent over 10 years as Senior Manager at PWC focusing on the Pharma Industry.

Scientific Advisory Board

Scientific Team comprising of world-renowned specialists in their respective fields, providing hands-on involvement and valuable assistance to JUNS.

Li-Huei Tsai,
4 Ph.D.



Li-Huei is Professor and Director of the Picower Institute for Learning and Memory at the Massachusetts Institute of Technology and one of the leading Alzheimer's researchers in the world. Actively guiding us in planning of our AD studies.

Raymond Turner,
MD, Ph.D.



Professor of Neurology and Director of the Memory Disorders Program at Georgetown University Medical Center, Washington, DC. He earlier conducted an Alzheimer's trial with resveratrol generating positive data. Can't wait to be the Principal Investigator for our Phase II trial in Alzheimer's Disease.

Charbel Moussa,
MBBS Ph.D.



Associate Professor of Neurology. Director-Laboratory for Dementia and Parkinsonism. Department of Neurology Georgetown University Medical Center.

W. Dalton Dietrich III,
Ph.D.



Scientific Director of The Miami Project; Kinetic Concepts Distinguished Chair in Neurosurgery; Sr. Associate Dean for Discovery Science; Co-Director, Institute for Neural Engineering; Professor, Neurological Surgery, Neurology, Biomedical Engineering and Cell Biology

Shaun Brothers,
Ph.D., MBA



Shaun is our lead researcher in pre-clinical development of rare diseases. Associate Professor at U of Miami and one of our Co-Founders.

Claes Wahlestedt,
MD, Ph.D.



Our CMO and Co-Founder who primarily works as Professor at U of Miami. Long time leading roles as research head at large pharma companies e.g., AZ and Pfizer.

Thank You

NASDAQ: JUNS

Contacts:

c.rosen@jupiterneurosciences.com

a.rosen@jupiterneurosciences.com

a.silva@jupiterneurosciences.com

